Creative Medical Technology Holdings, Inc. (CELZ)
Automate Your Wheel Strategy on CELZ
With Tiblio's Option Bot, you can configure your own wheel strategy including CELZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CELZ
- Rev/Share 0.0071
- Book/Share 4.0696
- PB 0.5529
- Debt/Equity 0.0
- CurrentRatio 27.3895
- ROIC -0.7754
- MktCap 5817701.0
- FreeCF/Share -3.0271
- PFCF -0.9703
- PE -0.7318
- Debt/Assets 0.0
- DivYield 0
- ROE -0.8526
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Creative Medical Technology Holdings, Inc. (CELZ) and 89BIO (ETNB) have performed compared to their sector so far this year.
Read More
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study
Read More
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing in regenerative medicine solutions for immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced compelling mid-term follow-up data from its StemSpine® pilot study utilizing its AlloStem™ cells for the treatment of chronic lower back pain. The pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility.
Read More
About Creative Medical Technology Holdings, Inc. (CELZ)
- IPO Date 2015-11-06
- Website https://www.creativemedicaltechnology.com
- Industry Biotechnology
- CEO Mr. Timothy Warbington
- Employees 4